Will This Beaten-Down Stock Bounce Back? 3 Things to Know
Ocugen (NASDAQ: OCGN) has given vaccine investors a roller0coaster ride over the past year or so. It started out by soaring more than 700% in a few days after saying it would co-commercialize Bharat Biotech's coronavirus vaccine candidate -- Covaxin -- in the U.S. But as the project met bumps along the road, so did the share price. Today, Ocugen still hasn't commercialized Covaxin in the U.S. And the stock has lost more than 50% year to date.
This may look grim. But the U.S. Food and Drug Administration (FDA) recently delivered Ocugen some good news. The regulatory agency lifted its clinical hold on Ocugen's vaccine trial. Is this enough to push the stock higher? Before you snap up Ocugen shares, here are three things to know.
Image source: Getty Images.
Source Fool.com
